SCHEMBL863065

SCHEMBL863065

CCCCCCOCCOCCOCCOCCOCCOCCOc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.57
FOXM1 Q08050 1/20 0.54
NR5A1 Q13285 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
USP2 O75604 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
CYP3A4 P08684 1/20 0.54
MAPK1 P28482 1/20 0.54
CASP1 P29466 1/20 0.54
SLCO1B3 Q9NPD5 1/20 0.54
SLCO1B1 Q9Y6L6 1/20 0.54
CHRNB2 P17787 1/20 0.52
CHRNB4 P30926 1/20 0.52
CHRNA3 P32297 1/20 0.52
CHRNA7 P36544 1/20 0.52
CHRNA4 P43681 1/20 0.52
MGLL Q99685 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15923575 0.92 LTA4H (0.66) LTA4HNR5A1SMN1; SMN2MEN1KMT2A
SCHEMBL27974031 0.92 LTA4H (0.66) LTA4HNR5A1SMN1; SMN2MEN1KMT2A
SCHEMBL30539400 0.91 LTA4H (0.68) LTA4HNR5A1SMN1; SMN2MEN1KMT2A
SCHEMBL320403 0.87 CHRNA7 (0.58) LTA4HFOXM1SMN1; SMN2LMNACHRNB2
SCHEMBL9192236 0.87 LTA4H (0.68) LTA4HNR5A1SMN1; SMN2MEN1KMT2A
SCHEMBL969026 0.87 LTA4H (0.68) LTA4HNR5A1SMN1; SMN2MEN1KMT2A
SCHEMBL2487343 0.87 LTA4H (0.68) LTA4HNR5A1SMN1; SMN2MEN1KMT2A
SCHEMBL1417436 0.87 LTA4H (0.68) LTA4HNR5A1SMN1; SMN2MEN1KMT2A
SCHEMBL2484231 0.87 LTA4H (0.68) LTA4HNR5A1SMN1; SMN2MEN1KMT2A
SCHEMBL2487018 0.87 LTA4H (0.68) LTA4HNR5A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143366-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2012-03-27 US disclosed
US-8143366-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2012-03-27 US disclosed
US-20100081782-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME EKWURIBE NNOCHIRI N 2010-04-01 US disclosed
US-20100081782-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME EKWURIBE NNOCHIRI N 2010-04-01 US disclosed
US-7625995-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2009-12-01 US disclosed
US-7625995-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2009-12-01 US disclosed
US-20080146778-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME BIOCON LIMITED (IN) 2008-06-19 US disclosed
US-20080146778-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME BIOCON LIMITED (IN) 2008-06-19 US disclosed
US-7335751-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2008-02-26 US disclosed
US-7335751-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2008-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146778-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME ALK, AOX1, OGFR LTA4H 505/4885FOXM1 3964/4885NR5A1 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.